News Conference News ESC 2025 Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF Michael O'Riordan August 29, 2025
News Opinion Editor's Corner ESC 2025 What’s Going to Be Hot at ESC Congress 2025? Michael O'Riordan August 25, 2025
News Conference News ESC 2022 COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19 Todd Neale September 01, 2022
News Conference News ESC 2022 Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration Michael O'Riordan August 29, 2022
News Conference News ESC 2022 PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 Michael O'Riordan August 27, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Conference News ESC 2021 New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy Michael O'Riordan September 03, 2021
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Conference News ESC 2020 Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF Michael O'Riordan August 31, 2020
News Conference News ESC 2020 Trimetazidine Safe but Not Protective Long-term After PCI Caitlin E. Cox August 30, 2020
News Conference News ESC 2019 CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients Shelley Wood September 03, 2019
News Conference News ESC 2018 My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More Shelley Wood September 14, 2018
News Conference News ESC 2018 Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND Michael O'Riordan August 26, 2018
News Conference News ESC 2018 Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE Shelley Wood August 26, 2018
News Conference News ESC 2018 ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More Shelley Wood August 20, 2018
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017
News Opinion Editor's Corner ESC 2016 My Takeaways From ESC 2016: Eye-Rolling, Disappointments, and a Sobering Comeuppance Shelley Wood September 08, 2016
News Conference News ESC 2016 ICDs Do Not Reduce Mortality in Patients With HF Not Caused by Coronary Artery Disease: DANISH Michael O'Riordan August 28, 2016
News Conference News ESC 2012 Stem Cells, Nanoparticles Appear to be an Antidote to Atherosclerosis Caitlin E. Cox August 29, 2012